Want to see HK:6978 full AI Analyst Report?
Immunotech Biopharm Ltd (6978) Stock Statistics & Valuation Metrics
Total Valuation
Immunotech Biopharm Ltd has a market cap or net worth of HKD 222.30M. The enterprise value is HKD 718.18M.
- Market Cap
- HKD 222.30M
- Enterprise Value
- HKD 718.18M
Share Statistics
Immunotech Biopharm Ltd has 617,500,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 617,500,800
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Immunotech Biopharm Ltd’s return on equity (ROE) is 16.56 and return on invested capital (ROIC) is -32.83%.
- Return on Equity (ROE)
- 16.56
- Return on Assets (ROA)
- -0.38
- Return on Invested Capital (ROIC)
- -32.83%
- Return on Capital Employed (ROCE)
- -1.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.22M
- Employee Count
- 189
- Asset Turnover
- 0.00
- Inventory Turnover
- 11.92
Valuation Ratios
The current PE Ratio of Immunotech Biopharm Ltd is -1.09. Immunotech Biopharm Ltd’s PEG ratio is -0.03.
- PE Ratio
- -1.09
- PS Ratio
- 0.00
- PB Ratio
- -2.25
- Price to FCF
- -1.38
- Price to Operating Cash Flow
- -1.56
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Immunotech Biopharm Ltd had revenue of 0 and earned -230.78M in profits. Earnings per share was -0.42.
- Revenue
- 0
- Gross Profit
- -53.87M
- Operating Income
- -155.80M
- Pretax Income
- -230.91M
- Net Income
- -230.78M
- EBITDA
- -168.80M
- Earnings Per Share (EPS)
- -0.42
Cash Flow
In the last 12 months, operating cash flow was -120.53M and capital expenditures -15.44M, giving a free cash flow of -135.97M billion.
- Operating Cash Flow
- -120.53M
- Free Cash Flow
- -135.97M
- Free Cash Flow per Share
- -0.22
Dividends & Yields
Immunotech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -72.23%
- Earnings Yield
- -89.72%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- -88.20%
- 50-Day Moving Average
- 0.39
- 200-Day Moving Average
- 1.27
- Relative Strength Index (RSI)
- 41.36
- Average Volume (3m)
- 104.08K
Important Dates
Immunotech Biopharm Ltd upcoming earnings date is Mar 19, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 21, 2026
- Next Earnings Date
- Mar 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Immunotech Biopharm Ltd as a current ratio of 0.35, with Debt / Equity ratio of -3159.87%
- Current Ratio
- 0.35
- Quick Ratio
- 0.34
- Debt to Market Cap
- 0.23
- Net Debt to EBITDA
- -2.29
- Interest Coverage Ratio
- -23.50
Taxes
In the past 12 months, Immunotech Biopharm Ltd has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Immunotech Biopharm Ltd EV to EBITDA ratio is -5.00, with an EV/FCF ratio of -3.86.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.00
- EV to Free Cash Flow
- -3.86
- EV to Operating Cash Flow
- -4.35
Balance Sheet
Immunotech Biopharm Ltd has HKD 65.93M in cash and marketable securities with HKD 402.12M in debt, giving a net cash position of -HKD 336.19M billion.
- Cash & Marketable Securities
- HKD 65.93M
- Total Debt
- HKD 402.12M
- Net Cash
- -HKD 336.19M
- Net Cash Per Share
- -HKD 0.54
- Tangible Book Value Per Share
- -HKD 0.16
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Immunotech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 21.82%
Scores
- Smart Score
- 5
- AI Score
- 41.75